Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
foresiGHt: Lonapegsomatropin in Adults With Growth Hormone Deficiency
NCT04615273Phase 3Completed
- Sponsor
- Ascendis Pharma
- Start
- Dec 2020
- Primary completion
- Nov 2023
- Modality
- Recombinant Proteins and Enzymes, Prodrugs/Conditional Activator Small Molecules
- Countries
- 24
01
Overview
Phase 3, randomised, double-blind trial of lonapegsomatropin in growth hormone deficiency (GHD) (3 arms), sponsored by Ascendis Pharma. Primary endpoint: Change From Baseline in Trunk Percent Fat at 38 weeks. Started Dec 2020; status: completed.
02
Drugs
lonapegsomatropin
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NCT04615273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04615273.